Sugi Predict

Sugi Predict / Compounds / SCHEMBL6168510

SCHEMBL6168510

SCHEMBL6168510

CC(F)(CCC(CC(O)[CH]Cc1ccccc1)C(=N)N)C(N)=O

nearest known ligand 0.34

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 6/20 0.34
▸ NPC1 O15118 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ GRIK1 P39086 1/20 0.32
▸ MMP1 P03956 2/20 0.31
▸ MMP13 P45452 1/20 0.31
▸ MAPT P10636 2/20 0.30
▸ S1PR4 O95977 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ S1PR1 P21453 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30
▸ CPA1 P15085 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167494 0.92 CCR1 (0.40) CCR1GRIK1
SCHEMBL6169158 0.90 CCR1 (0.34) CCR1GRIK1MMP1MMP13
SCHEMBL27565233 0.88 CCR1 (0.38) CCR1
SCHEMBL4064274 0.88 CCR1 (0.41) CCR1TSHR
SCHEMBL4064042 0.88 CCR1 (0.43) CCR1MMP1MMP13MAPT
SCHEMBL6832277 0.88 CCR1 (0.41) CCR1TSHR
SCHEMBL6169667 0.88 CCR1 (0.43) CCR1MMP1MMP13MAPT
SCHEMBL6675011 0.86 CCR1 (0.43) CCR1ALDH1A1LMNAKMT2A
SCHEMBL4058724 0.86 CCR1 (0.35) CCR1TSHRMMP1MMP13MAPT
SCHEMBL6169055 0.84 MEN1 (0.32) CCR1TSHRGRIK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1498417-A1 Heterocyclic amide derivatives Pfizer Products Inc. (US) 2005-01-19 — — EP disclosed
WO-2004039375-A1 METHODS OF USING CCR1 ANTAGONISTS AS IMMUNOMODULATORY AGENTS PFIZER PRODUCTS INC. (US) 2004-05-13 — — WO disclosed
US-20040087571-A1 Methods of using CCR1 antagonists as immunomodulatory agents PFIZER INC 2004-05-06 — — US disclosed
US-6689886-B2 TREATMENT OF INFLAMMATION AND OTHER IMMUNE DISORDERS PFIZER INC. 2004-02-10 — — US disclosed
US-20030204086-A1 Novel heterocyclic amide derivatives BROWN MATTHEW F (US) 2003-10-30 — — US disclosed
US-6548671-B2 Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous PFIZER INC 2003-04-15 — — US disclosed
EP-1252154-A1 HETEROCYCLIC AMIDE DERIVATIVES Pfizer Products Inc. (US) 2002-10-30 — — EP disclosed
US-20020132810-A1 Novel heterocyclic amide derivatives BROWN MATTHEW F (US) 2002-09-19 — — US disclosed
WO-2001057023-A1 HETEROCYCLIC AMIDE DERIVATIVES PFIZER PRODUCTS INC. (US) 2001-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030204086-A1 Novel heterocyclic amide derivatives HAX1, ARG1, CXCR2 CCR1 58/4885NPC1 2742/4885TSHR 3391/4885
US-20040087571-A1 Methods of using CCR1 antagonists as immunomodulatory agents CCR1, CCR3, CCRL2 CCR1 1/4885NPC1 1232/4885TSHR 1258/4885
US-20020132810-A1 Novel heterocyclic amide derivatives ARG1, IL4, ARG2 CCR1 32/4885NPC1 1088/4885TSHR 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.